PMID- 34388598 OWN - NLM STAT- MEDLINE DCOM- 20220125 LR - 20220125 IS - 1872-6968 (Electronic) IS - 0303-8467 (Linking) VI - 208 DP - 2021 Sep TI - Clinical characteristics and outcomes of chronic subdural hematoma in patients with a history of antiplatelet therapy. PG - 106817 LID - S0303-8467(21)00346-2 [pii] LID - 10.1016/j.clineuro.2021.106817 [doi] AB - OBJECTIVE: Chronic subdural hematoma (CSDH) is a common neurosurgical disease. Many patients with CSDH take antiplatelet (AP) drugs. Several studies have focused merely on the relationship between AP drug use and recurrence without deeply analyzing the specific clinical features of these patients. The primary objective of this study was to investigate the detailed clinical characteristics and outcomes of CSDH patients with a history of AP therapy. METHODS: A total of 1181 CSDH patients over 40 years of age who received burr-hole craniostomy were enrolled. Clinical information, computed tomographic findings, and data on long-term outcomes and recurrence among these patients were gathered. We divided these patients into two groups according to whether they had a history of AP therapy. Percentages and chi2 tests were applied for categorical variables. Standard deviations and 2-sided unpaired t-tests were applied for continuous variables. Univariate and multivariate logistic regression analyses were performed to identify independent factors of the outcomes (6 months after discharge). RESULTS: AP therapy was not related to the outcomes of patients with CSDH (P = 0.48), and there were no differences in recurrence between the AP and non-AP group. Only Bender grade (P < 0.01, B = -3.14, Exp (B) = 0.04, 95% CI 0.01-0.29) was associated with the outcomes of patients in the AP group. The incidence of complications in the AP group was higher than that in the non-AP group (P < 0.01). Postoperative thrombotic events may be more likely to occur in the AP group than in the non-AP group (P = 0.02). Patients in the AP group were older (P < 0.01) and had more comorbidities (P < 0.01). CONCLUSIONS: Patients treated with AP therapy had more complications. The outcomes of patients treated with AP therapy were associated with their status of admission. Patients treated with AP therapy were at greater risk for postoperative thrombotic events. The recurrence rate of CSDH did not appear to be affected by AP therapy. CI - Copyright (c) 2021 Elsevier B.V. All rights reserved. FAU - Yu, Xiaofan AU - Yu X AD - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. FAU - Wu, Liang AU - Wu L AD - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Electronic address: jasewl@sina.com. FAU - Ou, Yunwei AU - Ou Y AD - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Beijing Neurosurgical Institute, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, China; Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beihang University, Beijing, China. FAU - Xu, Long AU - Xu L AD - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. FAU - Guo, Xufei AU - Guo X AD - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. FAU - Yang, Cheng AU - Yang C AD - The Third Clinical Medical College, Ningxia Medical University, Yinchuan, China. FAU - Liu, Weiming AU - Liu W AD - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, China; Neurological Center, People's Hospital of Ningxia Hui Autonomous Region (The Third Clinical Medical College, Ningxia Medical University), Yinchuan, China. Electronic address: liuweimingnsok@sina.com. LA - eng PT - Journal Article DEP - 20210710 PL - Netherlands TA - Clin Neurol Neurosurg JT - Clinical neurology and neurosurgery JID - 7502039 RN - 0 (Platelet Aggregation Inhibitors) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - *Drainage MH - Female MH - Hematoma, Subdural, Chronic/*diagnosis/etiology/surgery MH - Humans MH - Male MH - Middle Aged MH - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use MH - Treatment Outcome MH - *Trephining OTO - NOTNLM OT - Antiplatelets OT - Characteristics OT - Chronic subdural hematoma OT - Outcomes OT - Recurrence EDAT- 2021/08/14 06:00 MHDA- 2022/01/27 06:00 CRDT- 2021/08/13 20:18 PHST- 2021/05/02 00:00 [received] PHST- 2021/07/06 00:00 [revised] PHST- 2021/07/06 00:00 [accepted] PHST- 2021/08/14 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2021/08/13 20:18 [entrez] AID - S0303-8467(21)00346-2 [pii] AID - 10.1016/j.clineuro.2021.106817 [doi] PST - ppublish SO - Clin Neurol Neurosurg. 2021 Sep;208:106817. doi: 10.1016/j.clineuro.2021.106817. Epub 2021 Jul 10.